Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3583 - VENTANA (SOLTI-1501): Antiproliferative Effect of the Addition of Oral Metronomic Vinorelbine to Endocrine Therapy in Luminal/HER2-negative Early Breast Cancer: A Window of Opportunity Trial


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Barbara Adamo


Annals of Oncology (2017) 28 (suppl_5): v43-v67. 10.1093/annonc/mdx362


B. Adamo1, J.A. Perez Fidalgo2, E. Ciruelos3, M. Vidal1, S. Blanch4, A. Lopez5, P. Gomez Pardo6, L. Murillo7, K. Amillano8, N. Martínez Jañez9, X. Gonzalez10, J. Canes Ruiz11, A. Prat1

Author affiliations

  • 1 Medical Oncology  , Hospital Clínic de Barcelona  , 8036 - Barcelona/ES
  • 2 Medical Oncology  , Hospital Clinico Universitario de Valencia, 46010 - Valencia/ES
  • 3 Medical Oncology  , Hospital Universitario 12 De Octubre, 28041 - Madrid/ES
  • 4 Medical Oncology  , Fundación Instituto Valenciano de Oncología, Valencia/ES
  • 5 Medical Oncology  , Hospital de León, Leon/ES
  • 6 Medical Oncology  , Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 7 Medical Oncology  , Hospital Clínico Universitario Lozano Blesa, Zaragoza/ES
  • 8 Medical Oncology  , Hospital Universitari Sant Joan de Reus, Reus/ES
  • 9 Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid/ES
  • 10 Medical Oncology  , Hospital Universitario Quirón Dexeus, 08028 - Barcelona/ES
  • 11 Scientific, SOLTI Breast Cancer Research Group, 08008 - Barcelona/ES


Abstract 3583


The cornerstone of luminal breast tumors treatment both in early and advanced settings is endocrine therapy (ET). Although extended adjuvant ET has demonstrated benefit, a significant percentage of patients relapse. In previous studies, the combination of ET with CDK4/6 inhibitors has shown unprecedented efficacy suggesting that inhibition of the cell cycle in combination with ET is a strategy to keep exploring. The efficacy and safety of metronomic VNB have been confirmed in preclinical and clinical studies and it is now considered a multi-mechanisms of action therapy that could offer advantages when combined with other drugs. VENTANA study is a “window-of-opportunity” trial designed to explore whether, similarly to CDK4/6 inhibitors, oral metronomic VNB in combination with endocrine therapy induces a superior antiproliferative effect than ET alone. We hypothesize that the synergistic biological effect of the combined treatment could be an alternative to CDK4/6 inhibitors in the treatment of luminal breast cancer patients.

Trial design

Pts are randomized (1:1:1) to receive LET 2.5mg daily, oral VNB 50mg 3 days a week, or the combination. After 3 weeks of treatment, pts undergo surgery. Pre- and post-treatment (surgical) samples will be analyzed for gene expression. The primary objective is to test if oral metronomic VNB and LET induce a superior anti-proliferative effect than either drug alone in pts with early BC defined as Luminal by PAM50. This will be evaluated by the expression of 11 proliferative genes contained in the PAM50 subtype predictor (BIRC5, CCNB1, CDC20, CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS and UBE2C) as surrogate signature biomarker of its anticancer activity. In addition, 560 BC-related gene signatures will also be analyzed. Enrollment started in July 2016 in 10 sites across Spain. To date, 47 patients have been included. We expect to report full study results by Spring 2018.

Clinical trial identification


Legal entity responsible for the study

SOLTI Breast Cancer Research Group


Pierre Fabre


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.